TB-500 vs IGF-1

TB-500 and IGF-1 represent distinct classes of research peptides with divergent mechanisms and evidence landscapes. TB-500, a synthetic fragment of thymosin beta-4, is studied for its roles in cell migration, wound healing, and inflammation modulation, with limited but promising human safety data. IGF-1, a 70-amino-acid protein central to growth hormone signaling, has a more established regulatory path, including FDA approval for specific deficiency states. Researchers must weigh TB-500's exploratory potential in tissue repair against IGF-1's well-documented metabolic and growth effects, considering each peptide's unique safety profiles and dosing requirements.

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.. It contains the active healing sequence Ac-LKKTETQ (MW ~889 g/mol), which promotes cell migration and tissue repair. Evidence includes a handful of human randomized controlled trials for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, TB-500 remains unapproved for therapeutic use in major markets and is banned by WADA and in horse racing. Key research claims include accelerated wound healing, reduced inflammation, and cardiac repair, but the evidence base is less mature than for IGF-1.

Insulin-like Growth Factor 1 (IGF-1) is a 70-amino-acid protein structurally similar to insulin, primarily produced by the liver in response to growth hormone. Recombinant human IGF-1 (mecasermin, brand name Increlex) is FDA-approved for severe primary IGF-1 deficiency (primary IGFD), where patients have normal or elevated GH but inadequate IGF-1. IGF-1 mediates many of GH's growth-promoting effects and circulates bound to IGF binding proteins, primarily IGFBP-3 in a ternary complex. Key research claims include treatment of primary IGFD, promotion of muscle growth, and neuroprotective effects. The evidence base is robust, with decades of clinical use and well-characterized pharmacokinetics.

TB-500 and IGF-1 target distinct research areas with minimal overlap. TB-500 is primarily investigated for injury recovery and anti-inflammatory applications, leveraging its role in cell migration and tissue repair. IGF-1, in contrast, is central to studies of growth, metabolism, and IGF-1 deficiency treatment. While both peptides have been explored for muscle-related effects, their mechanisms differ: TB-500 influences cytoskeletal dynamics and wound healing, whereas IGF-1 directly stimulates protein synthesis and cell proliferation via the IGF-1 receptor. Researchers should select based on whether the focus is tissue repair (TB-500) or growth/metabolic signaling (IGF-1).

TB-500: A safety-focused RCT in 40 healthy adults (2010) found minimal adverse effects with synthetic thymosin beta-4. No significant safety concerns have been reported in published human studies, and animal studies show minimal side effects. Common anecdotal side effects include injection site pain/redness, lightheadedness, mild headache, nausea, and fatigue. IGF-1: Hypoglycemia is the most common and serious adverse effect, with an FDA black box warning on Increlex—occurring in up to 50% of patients. It must be administered with a meal to reduce risk. Injection site reactions are also common. The safety profile of IGF-1 is better characterized due to its approved status.